Active	Status	Sponsor type	Region	Phase	Filter
2 Active 4 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
dihydroergotamine mesylate injection / Generic mfg.
2006-005672-41: Etude de l’efficacite de la dihydroergotamine par voie orale dans l’hypotension orthostatique de patients dysautonomiques	Ongoing	2	50	Europe	Ikaran LP 5 mg, Ikaran LP 5 mg	Pierre Fabre Médicament	hypotension orthostatique d’origine neurogène chez des patients dysautonomiques
ACTRN12623001201662: A Study to Evaluate Single Doses of Dihydroergotamine Mesylate Inhalation Powder and Dihydroergotamine Mesylate Intravenous in Healthy Adult Subjects	Completed	1	28			Syneos Health New Zealand Ltd, Vectura Inc.	Acute Migraine